Candel Therapeutics (CADL) EPS (Basic): 2020-2023
Historic EPS (Basic) for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$0.38.
- Candel Therapeutics' EPS (Basic) fell 123.53% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.30, marking a year-over-year decrease of 103.12%. This contributed to the annual value of -$1.74 for FY2024, which is 32.82% down from last year.
- According to the latest figures from Q4 2023, Candel Therapeutics' EPS (Basic) is -$0.38, which was down 31.03% from -$0.29 recorded in Q3 2023.
- Candel Therapeutics' EPS (Basic)'s 5-year high stood at $0.51 during Q4 2021, with a 5-year trough of -$1.46 in Q2 2021.
- Its 3-year average for EPS (Basic) is -$0.33, with a median of -$0.30 in 2023.
- Per our database at Business Quant, Candel Therapeutics' EPS (Basic) skyrocketed by 156.67% in 2021 and then tumbled by 900.00% in 2023.
- Candel Therapeutics' EPS (Basic) (Quarterly) stood at -$0.90 in 2020, then spiked by 156.67% to $0.51 in 2021, then crashed by 133.33% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
- Its EPS (Basic) was -$0.38 in Q4 2023, compared to -$0.29 in Q3 2023 and -$0.33 in Q2 2023.